Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 29, 2023

Overall Survival With [177]Lu-PSMA-617 vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Lancet Oncol 2023 Nov 30;[EPub Ahead of Print], MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, JC Goh, DA Pattison, TH Tan, ID Kirkwood, S Ng, RJ Francis, C Gedye, NK Rutherford, A Weickhardt, AM Scott, ST Lee, EM Kwan, AA Azad, S Ramdave, AD Redfern, W Macdonald, A Guminski, E Hsiao, W Chua, P Lin, AY Zhang, MR Stockler, SG Williams, AJ Martin, ID Davis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading